CD274 and hepatocellular carcinoma: Clinical trials with antibodies against PD-1 (nivolumab and pembrolizumab) and PD-L1 (atezolizumab) are under way in HCC patients (Pardoll, 2012[50]; Kudo, 2017[35]).